Literature DB >> 18523271

CD47 expression on T cell is a self-control negative regulator of type 1 immune response.

Salim Bouguermouh1, Vu Quang Van, Julie Martel, Patrick Gautier, Manuel Rubio, Marika Sarfati.   

Abstract

The cytokine milieu and dendritic cells (DCs) direct Th1 development. Yet, the control of Th1 polarization by T cell surface molecules remains ill-defined. We here report that CD47 expression on T cells serves as a self-control mechanism to negatively regulate type 1 cellular and humoral immune responses in vivo. Th2-prone BALB/c mice that lack CD47 (CD47(-/-)) displayed a Th1-biased Ab profile at steady state and after immunization with soluble Ag. CD47(-/-) mice mounted a T cell-mediated exacerbated and sustained contact hypersensitivity (CHS) response. After their adoptive transfer to naive CD47-deficient hosts 1 day before immunization with soluble Ag, CD47(-/-) as compared with CD47(+/+)CD4(+) transgenic (Tg) T cells promoted the deviation of Ag-specific T cell responses toward Th1 that were characterized by a high IFN-gamma:IL-4 cytokine ratio. Although selective CD47 deficiency on DCs led to increased IL-12p70 production, CD47(-/-)Tg T cells produced more IFN-gamma and displayed higher T-bet expression than CD47(+/+) Tg T cells in response to OVA-loaded CD47(-/-) DCs. CD47 as part of the host environment has no major contribution to the Th1 polarization responses. We thus identify the CD47 molecule as a T cell-negative regulator of type 1 responses that may limit unwanted collateral damage to maximize protection and minimize host injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18523271     DOI: 10.4049/jimmunol.180.12.8073

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

Review 1.  CD47: role in the immune system and application to cancer therapy.

Authors:  Seyed Mohammad Gheibi Hayat; Vanessa Bianconi; Matteo Pirro; Mahmoud R Jaafari; Mahdi Hatamipour; Amirhossein Sahebkar
Journal:  Cell Oncol (Dordr)       Date:  2019-08-14       Impact factor: 6.730

2.  Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy.

Authors:  Yismeilin R Feliz-Mosquea; Ashley A Christensen; Adam S Wilson; Brian Westwood; Jasmina Varagic; Giselle C Meléndez; Anthony L Schwartz; Qing-Rong Chen; Lesley Mathews Griner; Rajarshi Guha; Craig J Thomas; Marc Ferrer; Maria J Merino; Katherine L Cook; David D Roberts; David R Soto-Pantoja
Journal:  Breast Cancer Res Treat       Date:  2018-07-28       Impact factor: 4.872

3.  CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy.

Authors:  David R Soto-Pantoja; Masaki Terabe; Arunima Ghosh; Lisa A Ridnour; William G DeGraff; David A Wink; Jay A Berzofsky; David D Roberts
Journal:  Cancer Res       Date:  2014-10-08       Impact factor: 12.701

4.  Thrombospondin-1 derived from APCs regulates their capacity for allosensitization.

Authors:  Daniel R Saban; Felix Bock; Sunil K Chauhan; Sharmila Masli; Reza Dana
Journal:  J Immunol       Date:  2010-09-15       Impact factor: 5.422

5.  CD47 deficiency ameliorates autoimmune nephritis in Fas(lpr) mice by suppressing IgG autoantibody production.

Authors:  Lei Shi; Zhen Bian; Celia X J Chen; Ya-Nan Guo; Zhiyuan Lv; Caihong Zeng; Zhihong Liu; Ke Zen; Yuan Liu
Journal:  J Pathol       Date:  2015-07-14       Impact factor: 7.996

6.  Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation.

Authors:  Thomas W Miller; Sukhbir Kaur; Kelly Ivins-O'Keefe; David D Roberts
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

7.  CD47 Plays a Role as a Negative Regulator in Inducing Protective Immune Responses to Vaccination against Influenza Virus.

Authors:  Young-Tae Lee; Eun-Ju Ko; Youri Lee; Yu-Na Lee; Zhen Bian; Yuan Liu; Sang-Moo Kang
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

Review 8.  Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47.

Authors:  David R Soto-Pantoja; Erica V Stein; Natasha M Rogers; Maryam Sharifi-Sanjani; Jeffrey S Isenberg; David D Roberts
Journal:  Expert Opin Ther Targets       Date:  2012-10-27       Impact factor: 6.902

Review 9.  CD47: a potential immunotherapy target for eliminating cancer cells.

Authors:  F Kong; F Gao; H Li; H Liu; Y Zhang; R Zheng; Y Zhang; J Chen; X Li; G Liu; Y Jia
Journal:  Clin Transl Oncol       Date:  2016-02-01       Impact factor: 3.405

10.  A role for CD47 in the development of experimental colitis mediated by SIRPalpha+CD103- dendritic cells.

Authors:  Genevieve Fortin; Marianne Raymond; Vu Quang Van; Manuel Rubio; Patrick Gautier; Marika Sarfati; Denis Franchimont
Journal:  J Exp Med       Date:  2009-08-24       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.